Member Login
|
Site Map
|
Disclaimer
|
Contact
|
Bookmark
Advanced Search
Text Size
|
Thursday, July 29, 2010
Home
Site Map
About Neura.net
Editorial Board Biographies
Patricia K. Coyle, MD
Paul Fishman, MD, PhD
Corey C. Ford, MD, PhD
Edward J. Fox, MD, PhD
Hillel Panitch, MD
Andrew D. Siderowf, MD
Anthony Traboulsee, MD
Neura
Biosimilar/Biogeneric Medications
Benign Multiple Sclerosis
CME
Benign Multiple Sclerosis
References
Sidebar: Putting Benign MS in Context With Clinically Isolated Syndrome
Essential Tremor
References
Advances in Stem Cell Therapy for Neurodegenerative Diseases
References
Highlights From the Literature
Patient Tear-Out: Current Policy Governing Stem Cell Research
Neuromyelitis Optica/Devic’s Disease
CME
Neuromyelitis Optica/Devic’s Disease
References
Sports Brain Injuries and Neurodegenerative Disease
References
Quality of Life in Parkinson’s Disease
References
Highlights From the Literature
**Online Exclusive**
CSF Biomarkers for Incipient AD
Patient Tear-Out: Maintaining a Good Quality of Life While Living With PD
Huntington's Disease: An Overview
CME
Huntington's Disease: An Overview
References
CME
Understanding Progressive Multiple Sclerosis
References
MAO-B Inhibitors in Parkinson’s Disease
References
Highlights From the Literature
**Online Exclusive**
Highlights from the Literature
Patient Tear-Out: Dealing With End-of-Life Issues
Nondopaminergic Pathology, Treatments, and Trials in Parkinson’s Disease
CME
Nondopaminergic Pathology, Treatments, and Trials in Parkinson’s Disease
References
CME
Differentiating MS From Other Demyelinating Disorders
References
Neuroscience 2008 Round-Up
Highlights From the Literature
Patient Tear-Out: Your MS Management, Your Way
Alzheimer’s Disease Etiology, Diagnosis, & Current Management Options
Rapid Review: Alzheimer’s Disease Etiology, Diagnosis, and Current Management Options
**Online Exclusive**
Bonus AD Material
Table 1
References
Rooting Out the Mechanism of Neuropathic Pain
References
Meeting the Challenge: Predicting MS Outcomes
**Online Exclusive**
More Information on Cognitive Impairment in MS
References
Highlights from the Literature
Pharmacogenomic Analysis in Multiple Sclerosis
Hot Topic: Pharmacogenomic Analysis in Multiple Sclerosis
References
Lithium in Amyotrophic Lateral Sclerosis and Alzheimer’s Disease
References
Adherence to Self-Injectable Therapy in MS
References
NeurAlert: New FDA Advisory for Management of Mitoxantrone Therapy in Patients with MS
**Online Exclusive**
Archives
Mitochondria and Oxidative Stress: Pathogenetic Mechanisms in Parkinson’s Disease
Mitochondria and Oxidative Stress: Pathogenetic Mechanisms in Parkinson’s Disease
References
Gene Therapy in Parkinson’s Disease
References
B-Cell Immunity and MS
References
B Cells, Epstein-Barr Virus, and MS
References
Highlights From the Literature
Parents, Pesticides, and Proteins: Pathogenetic Mechanisms of Parkinson’s Disease
Parents, Pesticides,and Proteins: Pathogenetic Mechanisms of Parkinson’s Disease
References
MS Clinical Trials: Updates and Debates
References
Clinical Trial Design
References
Highlights From the Literature
**Online Exclusive** Highlights
Advanced Imaging Techniques and MS Pathology
Hot Topic: Advanced Imaging Techniques and MS Pathology
References
Controversy: Melanoma and Neurodegenerative Disease
References
Resources: Medicine and the Web
References
Highlights from the Literature
Parasitism and Multiple Sclerosis Risk
Parasitism and Multiple Sclerosis Risk
References
Oral Therapies for Multiple Sclerosis
References
Falls in the Elderly
References
Highlights From the Literature
Experimental Autoimmune Encephalomyelitis and MS Drug Development
Of Mice and Men: Experimental Autoimmune Encephalomyelitis and MS Drug Development
References
Statins, Low Cholesterol, and Parkinson’s Disease
References
Molecular Biology of Huntington’s Disease
References
Highlights From the Literature
Issues in PPMS
Issues in Primary–Progressive Multiple Sclerosis
References
Vitamin D and Multiple Sclerosis
References
Parkinson’s Disease Therapy and Valvular Heart Disease
References
Fatigue in MS
References
Saving the Neuron-Part 3
Hot Topic: Saving the Neuron: Part 3
References
MS Therapies: A Look Ahead
References
Meeting Reports: Hot Topics From the Annual Meeting of the SFN
Highlights From the Literature
Saving the Neuron-Part 2
Hot Topic: Saving the Neuron: Part 2
References
Glial Cells: A Primer
References
Pediatric Multiple Sclerosis
References
Highlights From the Literature
Saving the Neuron-Part 1
Hot Topic: Saving the Neuron: Part 1
References
Management of Parkinson’s Disease: Current Approaches and Future Prospects
References
Perspectives on Long-Term Management of Multiple Sclerosis
**Online Exclusive** A Delicate Balance: Assessing the Newcomer
References
References
Highlights From the Literature
**Online Exclusive** Highlights
The Immune System and Its Role in MS-Part 3
Hot Topic: The Immune System and Its Role in MS: Part 3
Monoclonal Antibodies to Treat MS: Update on Natalizumab and TGN1412
**Online Exclusive** Summary Figure on Proposed Targets of Current MS Drugs
References
Huntington’s Disease: A Primer
References
Highlights From the Literature
**Online Exclusive** Highlights
The Immune System and Its Role in MS-Part 2
Hot Topic: The Immune System and Its Role in MS: Part 2
References
Statins and CNS Diseases
References
**Online Exclusive** Special Discussion: Statins and Their Use in CNS Diseases
Pregnancy in MS
References
**Online Exclusive** Pregnancy and MS: A Q&A With Dr. Patricia K. Coyle
Highlights From the Literature
The Immune System and Its Role in MS-Part 1
Hot Topic: The Immune System and Its Role in Multiple Sclerosis
References
Amyotrophic Lateral Sclerosis: A Primer
References
Treatments: Complementary and Alternative Medicine in the Treatment of Multiple Sclerosis
References
Highlights From the Literature
Neura Special Edition:
State of the Art Multiple Sclerosis Treatment
The Genetics of MS
References
Spotlight on Current RRMS Treatments
References
MS in Special Populations
References
Fall 2005
Toward Personalized Medicine for Neurodegenerative Disease
References
Differential Diagnosis of Parkinson’s Disease
References
Issues in Primary-Progressive Multiple Sclerosis
References
Highlights From the Literature
Spring 2005
The Genetics of Parkinson's Disease
References
Safety Profiles of the Immunomodulators in Multiple Sclerosis
Natalizumab Is Withdrawn From the Market and Clinical Trials
References
Multiple Sclerosis Variants and Masqueraders
References
Highlights From the Literature
Winter 2004
Emerging Neurological Infectious Diseases
References
Multiple Sclerosis: Potential New Drugs and Treatment Strategies
References
Perspectives From Practice: Patients and Clinical Trials
Quality of Life in Parkinson’s Disease
References
Highlights From the Literature
Fall 2004
Experimental Therapies for Alzheimer's Disease
References
Symptom Management in Multiple Sclerosis
References
Perspectives From Practice: MS Symptom Management
The Management of Levodopa-Induced Motor Fluctuations in Parkinson's Disease
Dopamine Agonists and Motor Fluctuations: Comment by Paul Fishman, MD, PhD
References
Highlights From the Literature
Summer 2004
Human Prion Diseases: A Primer
References
Vitamin D Supplementation in the Prevention of Multiple Sclerosis
References
Perspectives From Practice
References
Neuroprotective Strategies in the Treatment of Parkinson's Disease
Assessing Neuroprotection in Clinical Trials
References
Highlights From the Literature
Spring 2004
MRI Findings as a Predictor of CDMS
References
Perspectives From Practice
References
Postmarketing Surveillance of Drug Safety
References
Cannabis and Cannabinoids in Neurological Disease
References
Highlights From the Literature
Winter 2003
Managed Care Initiatives in AD
Costs of Other Chronic Neurological Diseases
References
References
Designing Office-Based Patient Education Programs
References
Infection and MS: The Controversy Continues
References
Highlights From the Literature
Fall 2003
MRI: Conventional and Experimental Applications
References
Focus on Magnetic Resonance Spectroscopy
References
Pregnancy and the Immune System in MS
References
NSAIDs in Alzheimer's Disease: The Controvery Continues
References
Highlights From the Literature
Summer 2003
MRI: Conventional and Experimental Applications
References
Focus on Magnetic Resonance Spectroscopy
References
Neurotrophic Growth Factors and Roles in Pathogenesis of Neurological Disease
References
Managed Care Perspective on Multiple Sclerosis
References
Highlights From the Literature
Spring 2003
Measuring Brain Atrophy in Alzheimer's Disease
Experimental Treatment of Alzheimer's Disease
References
Fatigue in Multiple Sclerosis: Common, Disabling, and Measurable
References
The Next Phase in Neurology: Neuroprotection
References
Differing Mechanisms of Actions of MS Therapies
Highlights From the Literature
Fall 2002
The Health Insurance Portability and Accountability Act (HIPAA): An Introduction
References
Treatment Adherence
Overcoming Injection Challenges
References
On the Horizon: Genetic Epidemiology
References
Highlights From the Literature
Spring 2002
Clinical Measurements of MS
Using Cognition as a Disease Marker: Pro and Con
References
Using MRI to Monitor CNS Diseases
References
Nurse Corner — Mental and Physical Fatigue: Considerations in MS
Selected Readings
References
Highlights From the Literature
Winter 2001
Multiple Sclerosis: An Overview
References
Making Strides: The Immunomodulator Story
References
Perspectives On Magnetic Resonance Imaging: An Interview With Corey C. Ford, MD, PhD
References
Highlights From the Literature
Neura Quarterly e-Newsletter
Neura Quarterly e-Newsletter (Spring 2009)
Neura Quarterly e-Newsletter (Fall 2009)
Neura Quarterly e-Newsletter (Winter 2009)
Neura Quarterly e-Newsletter (Winter 2010)
Neura.net Podcasts
Neura.net NeuraPod Frequently Asked Questions
Archives
Congress Coverage
MDS 2010
CMSC 2010
AAN 2010
ECTRIMS 2009
Updates on Oral Therapies
Conversion to MS
Long-Term Treatment Effects of Immunosuppressant Therapies
JC Virus Detection
Inflammation and Neurodegeneration Are Not Independent
Understanding Progressive Forms of MS
DMT Effects on Disease Severity and Progression
Late-Breaking News on Investigational Therapies
MS Cognition: Predictors and Treatment Effects
Understanding Neutralizing Antibodies
Measuring Quality of Life in MS Patients
Data Suggest Neuroprotective Effects
Immune Cell Effects of Oral Therapies
B Cells: Disease and Treatment Effects
Treatment Reduces MS Spasticity
Long-Term Outcomes of Progressive MS Subtypes
Posttreatment Activity and JC Virus
Prevalence of CAM Use in the US
Dental Care Overlooked in MS Patients
MDS 2009
Racial Disparity in Parkinson's Disease Treatment
New Therapies Under Study
Findings in Early Parkinson's Disease
Extended Release Formulations vs Immediate Release Formulations in Advanced Parkinson's Disease
Using Telephones to Treat and Monitor Patients
Late-Breaking Updates
Huntington’s Disease: Minocycline and Manifest Time
Fatigue in Parkinson’s Disease
Cardiac Function and Blood Pressure Activity in Movement Disorders
A Spark of Creativity in Patients With PD
Assessing the Power of Placebo in PD Patients
The Impact of PD-Associated Psychiatric Issues
Risks and Consequences of Falls
A Genetic Link to Addictive Behaviors
PD Management Challenges and Patient Care
Perspective: Concerns of Family Caregivers
Multiple System Atrophy: Potential Management Strategies, Genetics
Gene-Based Therapy Trial Results
CMSC/ACTRIMS 2009
Optimizing Injectable Administration
Treatment Efficacy in RRMS
Clinical Trial Participation and Recruitment
Intense Immunosuppression and Stem Cell Transplantation in MS
Immune Cell Effects and Treatment Response Prediction
Predictive Power and Prevention of Falls
AAN 2009
Top News: Vitamin D & Multiple Sclerosis
Top News: Parkinson's Disease Etiology
Levodopa Combinations in Parkinson’s Disease
Nonmotor Symptoms & Lateral Hemisphere Involvement
Tyramine & MAO-B Inhibition
Clinically Isolated Syndrome
Alternate-Day Dosing in Multiple Sclerosis
Monoclonal Antibody Therapy in Multiple Sclerosis
Autologous Stem Cell Transplantation in Multiple Sclerosis
Cognitive & Physical Impairment in Multiple Sclerosis
Top News: Oral Therapies in Multiple Sclerosis
Top News in Parkinson's Disease
Top News in Alzheimer's Disease
Established Multiple Sclerosis Disease-Modifying Therapies
Deep Brain Stimulation in Parkinson's Disease
Detecting Dementia
Alzheimer’s Disease: Monoclonal Antibody Safety, Disease Modification, & Measures of Improvement
The Genetics of Treatment Response in MS
New MS Susceptibility Locus Identified
Findings From the New York State MS Consortium
Managing Parkinson’s Disease: Update
Multiple Sclerosis Research Findings
**ONLINE EXCLUSIVE** Multiple Sclerosis’ Impact on Quality of Life and Socioeconomic Factors
**ONLINE EXCLUSIVE** Smoking’s Role in Neurodegenerative Conditions
**ONLINE EXCLUSIVE** Lesion Correlations With Cognitive Impairment and Disability
**ONLINE EXCLUSIVE** Optical Analyses
**ONLINE EXCLLUSIVE** News on Clinically Isolated Syndrome
ANA 2008
Impact of Neurological Diseases on Daily Life
Delayed-Start Study Shows Benefit in Early Parkinson’s Disease
Surgical Approach Advantage Reported in Advanced Parkinson’s Disease
Early and Late PD
Sleep Effects in PD
Prion Disease Animal Models Help Discern Interactions and Therapeutic Targets
ANA 2008 Newsletter
Alzheimer’s Disease: Insights From Combination Therapy, Diabetes Research, Driving Ability
Alzheimer’s Disease Risk Factors: A Literature Review
Parkinson’s Disease and Parkinsonism
Iron and Cellular Degeneration: A Literature Review
ALS Findings: Correlations, Genetics, Statin Use
Differentiating ALS Types: A Literature Review
Untangling the Relationships Between Protein Misfolding Disorders: Preclinical Models
Protein Misfolding Disorders: A Literature Review
WCTRIMS 2008
What’s New
Evaluating the Oral Agent Findings Thus Far
Women's Issues
Looking at Long-Term (>5 Years) Outcomes for the DMTs
A Global Perspective on Natalizumab
Mitoxantrone Induction and in Combination With the Disease Modifiers
Oral Therapy Study Outcomes: A Global View
Examining Emerging Therapies & Approaches
From CIS to Clinically Definite MS
Results From Long-Term Clinical Trial Data
Pediatric MS Risk Factors & Disease Characteristics
Predicting MS Outcomes: Severity Scales, Genes, & Clinical Features
WCTRIMS 2008 Newsletter
Archives
ENS 2008
Herpesvirus Presence in MS Patients
Clinically Isolated Syndrome: Treatment Updates
Novel MS Therapies Under Investigation
Update on Immunosuppressive Therapy
Cognitive Impairment in MS Patients
Data Suggests Neuroprotective Effects of MS Treatments
CMSC 2008
Spotlight: Clinically Isolated Syndromes—The Rules of 10
Table 1. Why Diagnose and Treat CIS
Table 2. Differential Diagnoses to Consider When Ruling In MS
Table 3. Imaging Considerations When Diagnosing CIS
Platform Presentations: MS Disease Measurement and Treatment Update
Poster Presentations
AAN 2008
MS Trial Update 1: Investigational Therapies
Immunosuppressive Therapy
MS Patient Populations in Recent Clinical Trials
PD Trial Update
Diabetes and Dementia
Late-Breaking News in PD
MS Trial Update 2: Monoclonal Antibodies
B-Cell Depletion in MS
Gene Therapy’s Effects on Cognition in PD
Neutralizing Antibodies
Long-Term Imaging Studies
ALS and Italian Soccer Players
Late-Breaking News in MS and AD
Treatment of Alzheimer’s Disease: An Update
B Cells Have a Major Role in MS Pathogenesis
Smoking, Gender, and Neurodegenerative Risk
Monoclonal Antibody Therapy in MS
T Cells: Still Lead Players in MS Pathogenesis
Promoting Myelin Repair in Murine Model
New Approaches to Established MS Therapies
Low-Dose Mitoxantrone as Add-on Rescue Therapy in MS
Oral MS Therapies Continue to Show Benefit
Pharmacotherapy of Parkinson’s Disease: Clinical Trials
Deep Brain Stimulation Shows Effect on Gait
ECTRIMS 2007
Pediatric Multiple Sclerosis
Imaging Studies
Switching Therapies
Neutralizing Antibodies
Oral Therapies
Monoclonal Antibodies
Direct Comparison Data REGARDing Relapses and Safety
Viruses Implicated in MS Development, Relapses
Updates on Disease-Modifying Therapies
Direct-Comparison Trials Confirm Efficacy, Safety of DMTs
Monoclonal Antibody Trial Results
Understanding Brain Atrophy in MS
Iron Oxide Particles Better MS Lesion Marker Than Gd
Mitoxantrone Induction Therapy Prolongs the Effect of IFN Maintenance Therapy
EDSS and MRI May Predict Cognitive Status
Potential for Neuronal Preservation and Repair Encouraging
AAN 2007
New Oral Drugs Show Promise in MS
Therapeutic Assessment in Alzheimer’s Disease
Mediterranean Diet and Mortality in Alzheimer’s
Mediterranean Diet and Mortality in Alzheimer’s
Effect of Statins on Beta Interferon MS Therapy
Illumination Through Magnetization
Advances in Parkinson’s Disease Therapy
Early Evolution of Multiple Sclerosis
The BECOME Study’s Comparison Findings
Multiple Sclerosis Therapy Update
Monoclonal Antibodies as MS Therapy
**ONLINE EXCLUSIVE** Monitoring Mitoxantrone Safety
**ONLINE EXCLUSIVE** Daclizumab in MS
**ONLINE EXCLUSIVE** Apathy Predicts Cognitive Impairment
Racial and Socioeconomic Disparities in Patients With Parkinsonism
Update on MS Clinical Trials
Defining a Clinically Meaningful Difference in PD
High Levels of Amyloid Deposition Seen in Lewy Body Dementia
Cytokine Levels: Potential Biomarkers for MS Clinical Response
Enhanced Benefit Observed With Combination Therapy
RENEWing Mitoxantrone's Safety Profile
Alemtuzumab: Results in Refractory MS and as Initial Treatment
MDS 2006:
Neura Special Report
DBS in PD: Issues for 2007
MAO Inhibitor Effective Across Populations
Rasagiline Not Associated With the “Cheese Effect”
Nonmotor Symptoms: A Cross-Sectional Analysis
Treatment of PD: Today and Tomorrow
Trial Acronym Key
Gene Transfer Therapy May Lead to Improvement in PD Motor Function
Developments in Dyskinesia Research: Trial Design
Adenosine A
2A
Receptor Antagonist Shows Mixed Results
PD and Melanoma Risk
Early Addition of Entacapone Improves “Wearing Off”
Redefining Neuroprotection in Research
Gambling and DA Use
ECTRIMS 2006
Friday, September 29, 2006
Tuesday, October 3, 2006
**ON-LINE EXCLUSIVE**: Long-term Data Continues to Support Safety and Quality of Life
New Pharmacologic Modalities in MS
Comparative Study of Immunomodulatory Agents
Understanding Adherence to Therapy and Triggers for Discontinuation
The MS Severity Scale: A New Classification Tool
Can Early Axonal Loss Be Slowed or Reversed?
Managing Spasticity and Bladder Dysfunction in MS
The Evolving Definition of Benign MS
Cost of Relapses in Relapsing–Remitting MS
EFNS 2006
Update on Parkinson’s Disease Treatment
Improving PD Therapy Adherence: Issues and Answers
Assessing Quality of Life in Neurodegenerative Disorders
Developments in Multiple Sclerosis Research
Movement Disorders: Assessing Behavioral and Psychiatric Complications
New Perspectives, New Strategies in the Treatment of Neurodegenerative Diseases
The Search for New Therapies in Inflammatory/Demyelinating CNS Disease
AAN 2006
Thursday, April 6, 2006
Monday, April 10, 2006
**ON-LINE EXCLUSIVE**: Behavioral Benefits in Alzheimer’s
International Congress of Parkinson's Disease and Movement Disorders 2006
Friday, November 3, 2006
Monday, November 6, 2006
World Parkinson Congress
Friday, February 24, 2006
Monday, February 27, 2006
Advances in Therapy of Parkinson's Disease
Quality of Life in Parkinson’s Patients
The Parkinson’s Disease–Melanoma Connection
Mechanisms of Neuroprotective Therapy
Treatment-Resistant Motor Aspects of PD
Nonmotor Components of PD
Basic Research: Toward Preventing PD
Six Parkinson's Disease Genes Identified So Far
EFNS 2005 & ANA 2005
Optimizing Parkinson’s Disease Treatment
Low LDL Cholesterol: Parkinson’s Disease Risk Factor?
Alzheimer’s Disease: Cognitive and Functional Findings
Predicting Conversion From MCI to Alzheimer’s Disease
Treatment Trends in Multiple Sclerosis
Transcranial Magnetic Stimulation May Be Helpful in Amyotrophic Lateral Sclerosis
ECTRIMS 2005 & ACTRIMS 2005
Friday, September 30, 2005
Monday, October 3, 2005
Experimental Agents in SPMS
Long-Term Follow-up Commentary
International Congress of Parkinson's Disease and Movement Disorders 2005
European Federation of Neurological Societies 2005
Monday, September 19, 2005
Tuesday, September 20, 2005
**ON-LINE EXCLUSIVE**: Benefits of Memantine Confirmed in Everyday Medical Practice
European Neurological Society 2005
E-Exclusive Coverage
European Federation of Neurological Societies 2004
Monday, September 6, 2004
Tuesday, September 7, 2004
American Academy of Neurology 2004
Tuesday, April 27, 2004
Wednesday, April 28, 2004
Thursday, April 29, 2004
ECTRIMS 2004
Monday, October 11, 2004
Tuesday, October 12, 2004
International Congress of Parkinson's Disease and Movement Disorders 2004
Tuesday, June 15, 2004
Wednesday, June 16, 2004
European Neurological Society 2004
Tuesday, June 29, 2004
Wednesday, June 30, 2004
ECTRIMS 2003
Thursday, September 18, 2003
Friday, September 19, 2003
European Neurological Society 2003
American Academy of Neurology 2003
Tuesday, April 1, 2003
Wednesday, April 2, 2003
Thursday, April 3, 2003
ACTRIMS/ECTRIMS 2002
European Neurological Society 2002
American Academy of Neurology 2002
AAN 2009
Neura On-Site
Day 1
AAN 2009
Neura On-Site
Day 2
CMSC 2009
Neura On-Site
Day 1
CMSC 2009
Neura On-Site
Day 2
MDS 2009
Neura On-Site
Day 1
MDS 2009
Neura On-Site
Day 2
ECTRIMS 2009
Neura On-Site
Day 1
ECTRIMS 2009
Neura On-Site
Day 2
AAN 2010
Neura On-Site
Day 1
AAN 2010
Neura On-Site
Day 2
CMSC 2010
Neura On-Site
Day 1
CMSC 2010
Neura On-Site
Day 2
MDS 2010
Neura On-Site
Day 2
MDS 2010
Neura On-Site
Day 1
PD Perspectives
Professional Digest
Congress Coverage
Podcasts
Archives
Nurse Network
MS Scan
Issue 26 (2010)
Issue 25 (2010)
Issue 24 (2009)
Gender and Quality of Life
Clinical Trials for PPMS Yield Frustration and Hope
Research Roundup on MS Fatigue
Early Treatment for CIS: An Unfolding Success Story
Issue 23 (2009)
Barriers to Long-Term Maintenance of Care: Injection Anxiety
Improving Injection Experiences: A Round-Up From CMSC 2009
Assessing Two “Modern-Era” MS Studies
Editorial Board
Monographs
Advanced Practice Nursing
Monograph & Key Slides
Best Practices
Nursing Monograph
Key Issues
Nursing Monograph
Self-Study Materials
A Comprehensive Overview of MS Nursing, 2nd Edition
Editorial Board
Making Strides
Women and MS
Women and MS
Clinically Isolated Syndrome: What It Says About MS
A Profile of Benign MS
Respite Care for the Caregiver
Neuromyelitis Optica
Neuromyelitis Optica
Needles
Caring for the Caregiver
How You Can Help the MS Caregiver
Drug Development: From Lab to Pharmacy
Drug Development: From Lab to Pharmacy
Are You Interested in Participating in a Clinical Trial?
**Online Exclusive** Mouse and Man
Vision Problems in MS
Vision Problems in MS
Devic's Disease
Sexual Dysfunction in MS
You as a Partner in Care
Getting Outside Help
Adapting the Home
Depression and MS
Depression and MS
Depression During the Holidays
Pediatric MS
Pediatric MS Centers
Mobility Issues
Measuring MS
Measuring MS
MS on the Mind
Cognitive Problems on the Job
Diet and MS
Archives
On the Move With MS
Exercising With MS
Building Strength
Resources on Exercising With MS
Heat and MS
Tools to Help Keep Cool
Vacationing With MS
What if I experience a relapse while on vacation?
Special Edition: Your MS Questions and Answers
Frequently Asked MS Questions and Their Answers
Disease-Modifying Therapies (DMTs) for MS
Relationships, Intimacy, and Reproduction
Work and Disclosure of MS
Someone I Know Has MS
Resources
MS and the Web
MS and the Web
Special Tear-Out Page: In Search of Quality Information
Imaging Techniques and MS Research
**Online Exclusive** More Imaging Techniques
MS and Genetics
MS and Genetics
DNA, RNA, Genes: The Basics
Progress in Genetics Research
Managing Your Least Favorite Things: Have Medication,
Will Travel
Caregiving From a Distance
The History of MS
The History of MS
Managing Your Least Favorite Things: Heat-Related Pseudoattacks
Q & A: Getting the Most From Your Office Visits
MS Support Resources
Thinking of You, The Caregiving Partner: When A Child Has MS
Neuronal Repair and Protection in MS
Neuronal Protection and Repair in MS
Managing Your Least Favorite Things: Bladder and Bowel Problems
Bladder and Bowel Treatment Chart
Q & A: Your Questions Answered
Thinking of You, The Caregiving Partner: Rights in the Workplace
Staying on Track With Your MS Therapy
Staying on Track With Your MS Therapy
Research Data You Can Use: Reducing Injection-Site Reactions
Managing Your Least Favorite Things: The Cost of MS
Adding to the Cost of MS: Time Off From Work
**Online Exclusive** Private and Public Insurance
Q & A: Complementary & Alternative Medicines
Thinking of You, The Caregiving Partner: Marital Stress
MS in Special Populations
MS in Special Populations
Managing Your Least Favorite Things: Spasticity
Q&A: Your Questions Answered
Thinking of You, the Caregiving Partner: Intimacy
MS Drugs: An Overview of Potential Side Effects
MS Drugs: An Overview of Potential Side Effects
Update: The Touch™ Prescribing Program
Special Section: How to Read a Package Insert
Thinking of You, the Caregiving Partner: Getting Help for the Caregiver
MRI in Multiple Sclerosis
MRI in Multiple Sclerosis
Managing Your Least Favorite Things: Depression
Q&A: Your Questions Answered
Thinking of You, the Caregiving Partner: Dealing With Anger
Making Room for MS
Making Room for MS
Managing Your Least-Favorite Things: Medicare Part D Basics
Q&A: Clinical Trials
Thinking of You, the Caregiving Partner: Children & a Family Member With MS
Winter 2005
Understanding Progressive MS
Managing Your Least Favorite Things: Pain and Fatigue Revisited
Q & A: Your Questions Answered
Thinking of You: The Caregiving Partner—Mood Swings
Fall 2005
Making Sense of the Immune System in MS
Managing Your Least Favorite Things: Tremor and Speech Difficulties
Q & A: Men's Health
Thinking of You: The Caregiver Partner
Spring 2005
Your MS Primer
TYSABRI: Use Suspended
Managing Your Least Favorite Things: Injection-Site Reactions
Tips for Reducing Injection-Site Reactions
Q & A: Women's Health
Winter 2004
MS Treatment Update
Managing Your Least Favorite Things: Fatigue in MS
Q&A: Family and MS
Fall 2004
All About Relapses
Understanding Pseudoexacerbations
Managing Your Least Favorite Things: Pain
Q & A: Measuring MS
Summer 2004
Getting the Most from an Office Visit
Q & A: Neutralizing Antibodies
Managing Your Least Favorite Things: Bowel Problems
Spring 2004
Taking Control of Multiple Sclerosis
Managing Your Least Favorite Things: Sexual Dysfunction
Q & A: MRI
Winter 2003
Financial Planning in MS: Easing the Process
Q & A: Traveling
Managing Your Least Favorite Things: Gait Problems
Fall 2003
HIPAA: Knowing Your Medical Privacy Rights
What You Can Do to Safeguard Your Medical Information
How to File a Complaint
For More Information
Q & A: Self-injection
Managing Your Least Favorite Things: Bladder Problems
Bladder Problem Symptoms
Summer 2003
First-Person Perspective: Telling Your Family, Friends, and Employers About MS
How to Tell Your Family, Friends, and Employers About MS
References
Managing Your Least Favorite Things: Depression
References
Spring 2003
Multiple Sclerosis Treatment and Your Quality of Life
Are You Beginning Treatment for Multiple Sclerosis?
Managing Your Least Favorite Things: Spasticity
Resources
The West Wing
Fall 2002
MS Treatment Update
Sources
Least Favorite Things: Optic Neuritis
Editorial Board
Gail Hartley, MSN, NP, MSCN
Patricia M. Kennedy, RN, CNP, MSCN
Mary Ann Picone, MD
For Your Patients
Making Strides
Perspectives for Patients
Understanding the Discomfort: Insights Into Pain and How It Can Be Managed
The Importance of Adhering to Disease-Modifying Therapy
Gene Therapy for Parkinson’s Disease
New MS Therapies Are Being Explored
How MS is Visualized in the Brain and Spinal Cord
Reducing the Risk of Falling
Comprehensive Web Site Selection for MS Patients
**Online Exclusive** Fatigue in MS
Improved MS Treatments Expected Soon
MS in Children
Managing MS Today
Medicare Part D: Important Things You Should Know
Top 10 Things to Know
Pregnancy and Multiple Sclerosis
Complementary and Alternative Medicine: Separating Fact From Fiction
What to Expect From Your Disease-Modifying Therapy
Should You Get a Flu Vaccine When You Have Multiple Sclerosis?
Multiple Sclerosis: Dispelling the Myths
References
How Safe Are Your Multiple Sclerosis Medications?
What is PML?
Participating in Clinical Trials
References
Stroke and TIA
References
Parkinson's Disease
References
How to Manage Migraine
References
Getting to Know Your MS: Relapses
If Your MS Symptoms Worsen: Questions That Your Doctor May Ask (and That You May Want to Ask Yourself)
References
How to Cope With MS-Related Fatigue
References
Therapy Adherence: Why It's Important
Challenges to Adherence
Things You Can Do to Help You Adhere to Your Therapy
Getting to Know Your Multiple Sclerosis: Symptoms
How to Avoid Bowel Problems
References
Building Safety and Evacuation Preparedness
Fire Safety at Home for People With Disabilities: A Checklist
Support Services for Patients With MS and Other CNS Diseases: Internet Resources
References
Multiple Sclerosis and Your Immune System
Multiple Sclerosis Treatment and Your Quality of Life
Are You Beginning Treatment for Multiple Sclerosis?
Preventing Falls in Parkinson's Disease
References
Glossary
Material Request
Materials for Patients
Continuing Education
Neura
CME Activities
Web Links
Care Facilities
Education
Government
Press
Publications
Publishers
References
Resources
Search Engines and Portals
Societies
Neura.net is administered, managed, and populated by Expert Medical Education, a company dedicated to the education of healthcare professionals. The individual educational materials available here are supported by educational grants from Teva Neuroscience. This site is intended for U.S. audiences only. This Web site is for use by healthcare professionals only. It is not meant to serve as a substitute for a consultation with your physician. If you are a patient and would like to see Neura.net's educational material for patients,
click here
. Some discussions of drugs and devices contained on this Web site may include mention of uses that have not been evaluated by the United States Food and Drug Administration for safety and efficacy. Please consult complete prescribing information for any of the drugs and devices discussed before using them.
© 2010 Neura.net. All rights reserved.
